FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. VPI/95-09 DIV		SERIAL NO. 09/431,469		
1 Parcond	SUPPLEMENTAL INFORM STATEMENT BY APP	MATION DISC	CLOSURE	APPLICAN David M. Ar	rs mistead et al.		
2 4 2004 6	STATEMENT OF ACT	LIOAN	·	FILING DAT November 1		GROUP 1631	
		U.S. PAT	ENT DOCUME	NTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
m	⁷ 4,833,233	5/23/89	Carter	530	363	8/20/87	
nising	5,025,388	6/18/91	Cramer, III	364	496	8/26/88	
my	5,331,573	7/19/94	Balaji	364	496	12/14/90	
mon	5,353,236	10/4/94	Subbiah	364	499	4/23/92	
		FOREIGN F	PATENT DOCU	MENTS		1	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	AOITA ON
More	WO94/25860	11/10/94	PCT	G01N	24/00	•	
				* .			
	OTUED DOOUNE	ITO (In all relia		Data Dartina			
EXAMINER	OTHER DOCUME	119 (Incinain	g Author, Title,	Date, Pertinei	nt Pages, Etc.)	4.1	
INITIAL M					•,		
m	Andrus, M.B. and Schreiber, S.L., "Structure-Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin" J. Am. Chem. Soc., 115, pp. 10420-10421 (1993).						
892 1/4/01 MSM	Barford, D. and Keller, J.C., "Co-crystallization of the Catalytic Subunit of the Serine/Threonine Specific Protein Phosphatase 1 from Human in Complex with Microcystin LR", <u>J. Mol. Biol.</u> , 235, pp. 763-766 (1994)						
May	Bierer, B.E. et al., "Cyclosporin A and FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology" Curr. Opinion in Immunology, 5, pp. 763-773 (1993).						
M	Caffrey, M.V. et al. "Synthesis And Evaluation Of Dual Domain Macrocyclic FKBP12 Ligands" <u>Bioorg.</u> <u>Med. Chem. Lett.</u> , 4, pp. 2507-2510 (November, 1994).						
w	Campbell, I.D. and Dwek, R.A., "Diffraction" in <u>Biological Spectroscopy</u> , The Benjamin/Cummings Publishing Company, Menlo Park, CA, pp. 299-326 (1984).						
12 14101 M	Griffith, J.P. et al., "X-Ray Structure of Calcineurin Inhibited by the Immunophilin-Immunosuppressant FKBP12-FK506 Complex", Cell, 82, pp. 507-522 (1995)						
MAY	Guerini, D. and Klee, C.B Identification of a Polypro						(1989
M	Holt, D.A. et al., "Design, Crystal Structures of Thei	Synthesis, an	nd Kinetic Evalu	ation of High-	Affinity FKBP Lig	ands and th	ne X-ra

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

	<u> </u>				
FORM PTO-1	449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/95-09 DIV	SERIAL NO. 09/431,469		
SECOND SURPLEMENTAL INFORMATION DISCLOSURE COTATEMENT BY APPLICANT FEB 24 2004		APPLICANTS David M. Armistead et al.			
		FILING DATE November 1, 1999	GROUP 1631		
\	OTHER DOCUMENTS (Including Author, Title,	Date, Pertinent Pages, Etc.)			
EXAMINE BASS	A LA				
man	Hubbard, M.J. and Klee, C.B., "Functional Domain Structure of Calcineurin A: Mapping by Limited (Proteolysis", Biochemistry, 28, pp. 1868-1874 (1989)				
M	Kajihara, A. et al., "Protein Modelling Using a Chimera Reference Protein Derived From Exons" Protein Eng., 6, pp. 615-620 (1993).				
892 114101 MAM	Kissinger, C.R. et al., "Crystal Structures of Human Calcineurin and the Human FKBP12-FK506-Calcineurin Complex", Nature, 378, pp. 641-644 (1995)				
mor,	Kunz, J. and Hall, M.N. "Cyclosporin A, FK506 and Rapamycin: More Than Just Immunosuppression" TIBS, 18, pp. 334-338 (1993).				
my	Sharma, R.K. and Wang, J.H., "Calmodulin and Ca ²⁺ -Dependent Phosphorylation and Dephosphorylation of 63-kDa Subunit-Containing Bovine Brain Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase Isozyme" J. Biol. Chem., 261, pp. 1322-1328 (1986).				
non	Sträter, N. et al., "Crystal Structure of a Purple Acid Phosphatase Containing a Dinuclear Fe(III)-Zn(II) Active Site", Science, 268, pp. 1489-1492 (1995)				
not	Uhlin, U. et al., "Crystallization and Crystallographic Investigations of Ribonucleotide Reductase Protein R1 from Escherichia coli" FEBS Lett., 336, pp. 148-152 (1993).				
mon	Villafranca, J.E. et al., "Protein Serine/Threonine Phosphatases", Current Opinion in Biotech., 7, pp. 387-402 (1996)				
mon	Wilson, K.P. et al. "Comparative X-ray Structures of the Major Binding Protein for the Immunosuppressant FK506 (Tacrolimus) in Unliganded Form and in Complex with FK506 and Rapamycin" Acta Cryst., D51, pp. 511-521 (July, 1995).				
					

EXAMINER

Mg oforan

DATE CONSIDERED (

8/31/04

U.S. DEPARTMENT OF COMMERCE

ATTY. DOCKET NO.

APPLN. NO.

PATENT AND TRADEMARK OFFICE VPI/95-09 DIV 09/431,469 APPLICANTS CONFIRMATION NO. INFORMATION DISCLOSURE David Armistead et 8756 STATEMENT BY APPLICANT RECEIVED al. FILING DATE GROUP November 1, 1999 1631 OCT 1 5 2003 ENTER 1600/2900 U.S. PATENT DOCUMENTS FILING DATE EXAMINER DOCUMENT DATE NAME CLASS SUBCLASS IF INITIAL NUMBER APPROPRIATE FOREIGN PATENT DOCUMENTS EXAMINER TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS INITIAL NUMBER YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER INITIAL Balbes, L.M., et al., "A Perspective of Modern Methods in Computer-Aided Drug Design," in "Reviews in Computational Chemistry," K.B. Lipkowitz and D.B. Boyd, Eds., VCH Publishers, New York, 5: 337-379 (1994). Bartlett, P.A., et al., "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules," in "Molecular Recognition in Chemical and Biological Problems, "S.M. Roberts, Ed., Royal Society of Chemistry, Special Publication No. 78: 182-196 (1989). Böhm, H.-J., "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors," J. Comp. Aid. Molec. Design, 6: 61-78 (1992). Cohen, N.C., et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem., 33: 883-894 (1990).

EXAMINER

FORM PTO-1449

MG Moran

DATE CONSIDERED 7/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
OIPE
2002
OCT 0 3 2003
The state of
HYDE

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.
VPI/95-09 DIV	09/431,469
APPLICANTS David Armistead et al.	CONFIRMATION NO. 8756
FILING DATE	GROUP
November 1, 1999	1631

MAM	Eisen, M.B., et al., "HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site," Proteins Struct. Funct. Genet., 19: 199-221 (1994).
mm	Gillet, V., et al., "SPROUT: A Program for Structure Generation," J. Comp. Aid. Molec. Design, 7: 127-153 (1993).
mm	Goodford, P.J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," J. Med. Chem., 28: 849-857 (1985).
man man	Goodsell, D.S., and Olson, A.J., "Automated Docking of Substrates to Proteins by Simulated Annealing," Proteins Struct. Funct. Genet., 8: 195-202 (1990).
Mary	Guida, W.C., "Software for Structure-Based Drug Design," Curr. Opin. Struct. Biology, 4: 777-781 (1994).
mam	Kuntz, I.D., et al., "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol., 161: 269-288 (1982).
warg	Lauri, G. and Bartlett, P.A., "CAVEAT: A Program to Facilitate the Design of Organic Molecules," J. Comp. Aid. Molec. Design, 8: 51-66 (1994).
Mam	Martin, Y.C., "3D Database Searching in Drug Design," J. Med. Chem., 35: 2145-2154 (1992).
many many	Miranker, A., and Karplus, M., "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method," Proteins Struct. Funct. Genet., 11: 29-34 (1991)
my	Meng, E.C., et al., "Automated Docking with Grid-Based Energy Evaluation," Journal of Computational Chemistry, 13: 505-524 (1992).
MANY	Navia, M.A. and Murcko, M.A., "Use of Structural Information in Drug Design," Current Opinion in Structural Biology, 2: 202-210 (1992).
mail	Nishibata, Y., and Itai, A., "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation." Tetrahedron, 47: 8985-8990 (1991).

EXAMINER

Ma Moran

DATE CONSIDERED 7/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

OT PE

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.
VPI/95-09 DIV	09/431,469
APPLICANTS David Armistead et al.	CONFIRMATION NO. 8756
FILING DATE	GROUP
November 1, 1999	1631

BLANK	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.